Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival

Woohyung Lee(Ulsan College), Song Cheol Kim(Ulsan College), Minyoung Oh(Ulsan College), Dae Wook Hwang(Asan Medical Center), Kyu‐pyo Kim(Ulsan College), Baek‐Yeol Ryoo(Asan Medical Center), Jaewoo Kwon(Ulsan College), Jae Seung Kim(Ulsan College), Ki Byung Song(Ulsan College), Eunsung Jun(Asan Medical Center), Yejong Park(Ulsan College), Changhoon Yoo(Ulsan College), Jae Hoon Lee(Ulsan College), Seo Young Park(Korea National Open University), Jae Ho Jeong(Ulsan College), Heung-Moon Chang(Ulsan College)
British journal of surgery
May 28, 2021
10.1093/bjs/znab229
Cited by 36

Related Papers

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472